James R. Empfield - 12 Aug 2022 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
EVP, Drug Discovery
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
12 Aug 2022
Net transactions value
-$2,212,140
Form type
4
Filing time
16 Aug 2022, 17:36:13 UTC
Previous filing
14 Mar 2022
Next filing
14 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $62,000 +20,000 +200% $3.10* 30,000 12 Aug 2022 Direct
transaction XENE Common Shares Options Exercise $213,750 +45,000 +150% $4.75* 75,000 12 Aug 2022 Direct
transaction XENE Common Shares Tax liability $275,911 -7,257 -9.7% $38.02 67,743 12 Aug 2022 Direct F1
transaction XENE Common Shares Sale $1,365,853 -35,868 -53% $38.08 31,875 12 Aug 2022 Direct F2
transaction XENE Common Shares Sale $846,125 -21,875 -69% $38.68 10,000 12 Aug 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -20,000 -100% $0.000000* 0 12 Aug 2022 Common Shares 20,000 $3.10 Direct F4
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -45,000 -100% $0.000000* 0 12 Aug 2022 Common Shares 45,000 $4.75 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on August 11, 2022 for purposes of net settlement calculations.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.5101 to $38.5029, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.6084 to $38.7884, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The shares subject to the option are fully vested and exercisable.